2024
Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV
Pelchen-Matthews A, Mocroft A, Ryom L, Ross M, Sharma S, Coca S, Achhra A, Cornell E, Tracy R, Phillips A, Alonso M, Toulomi G, Agan B, Medland N, Wyatt C, Group I. Long-term impact of immediate versus deferred antiretroviral therapy on kidney health in people with HIV. Kidney International 2024, 106: 136-144. PMID: 38697479, PMCID: PMC11193627, DOI: 10.1016/j.kint.2024.04.010.Peer-Reviewed Original ResearchHuman immunodeficiency virusUrine albumin/creatinine ratioDeferred antiretroviral therapyChronic kidney diseaseStrategic Timing of AntiRetroviral TreatmentAntiretroviral therapyNo significant differenceTreatment armsFollow-upAnnual rate of eGFR declineRate of eGFR declineTiming of AntiRetroviral TreatmentEarly ARTART-naive adultsCD4 cell countImmediate antiretroviral therapySignificant differenceKidney-related deathLong-term safetyKidney healthStandard of careComprehensive follow-upImmunodeficiency virusAlbumin/creatinine ratioEGFR decline
2015
Kidney disease in antiretroviral‐naïve HIV‐positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial
Achhra A, Mocroft A, Ross M, Ryom L, Lucas G, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell J, Wyatt C, Group I. Kidney disease in antiretroviral‐naïve HIV‐positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Medicine 2015, 16: 55-63. PMID: 25711324, PMCID: PMC4341947, DOI: 10.1111/hiv.12234.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseCD4 cell countPrevalence of CKDART-naïve adultsGlomerular filtration rateUrine proteinCell countAntiretroviral therapyBaseline characteristicsKidney diseaseFiltration rateHigher CD4 cell countsTraditional CKD risk factorsCKD risk factorsHigher CD4 countsCells/μLCells/μL.AntiRetroviral Treatment (START) studyClinical trial participantsRace/ethnicityCD4 countHIV infectionRisk factorsLow prevalenceTrial participants